{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:34:45Z","timestamp":1792470885078,"version":"4.5.0"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T00:00:00Z","timestamp":1357776000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2013,1]]},"abstract":"Study Objective<\/jats:title>To provide clinicians with an understanding of the comparative occurrence of tigecycline and pancreatitis, and to provide any clinically relevant characteristics that may be useful in identifying the patients at risk.<\/jats:p><\/jats:sec>Design<\/jats:title>Retrospective cohort study.<\/jats:p><\/jats:sec>Data Source<\/jats:title>Spontaneous reports in the United States Food and Drug Administration (FDA) Adverse Event Reporting System (AERS<\/jats:styled-content>) database generated between J<\/jats:styled-content>anuary 1997 and D<\/jats:styled-content>ecember 2010.<\/jats:p><\/jats:sec>Patients<\/jats:title>Sixty\u2010two patients who experienced pancreatitis while receiving tigecycline therapy.<\/jats:p><\/jats:sec>Measurements and Main Results<\/jats:title>Disproportionality analysis with B<\/jats:styled-content>ayesian correction methodology was used to compare tigecycline with all other agents listed in the AERS<\/jats:styled-content>. Disproportionality analysis uses an adverse event relative reporting ratio (RRR<\/jats:styled-content>) to compare the occurrence of a specific adverse event with an index drug of interest to the occurrence of the same adverse event with similar agents or with all other FDA<\/jats:styled-content>\u2010approved prescription drugs. The value was considered meaningful if the 5th percentile of the distribution of the RRR<\/jats:styled-content> (RRR<\/jats:styled-content>05<\/jats:sub>) was 2 or greater. Our review identified 62 potential cases of tigecyline\u2010related pancreatitis. An RRR<\/jats:styled-content>05<\/jats:sub> score of 10.4, 10.38, and 2.87 was determined for tigecycline\u2010related pancreatitis compared with all other agents, systemic antibiotics, and select tetracyclines listed in the AERS,<\/jats:styled-content> respectively. In addition, a sex\u2010based RRR<\/jats:styled-content>05<\/jats:sub> score was higher in women versus men (14.432 vs 3.125) when tigecycline was compared with all agents in the AERS<\/jats:styled-content>.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Our analysis suggests a quantitative signal between tigecycline use and pancreatitis; however, given the limitations of our study, a cause\u2010and\u2010effect relationship cannot be inferred. Thus, additional rigorous scientific analyses are warranted to explore these findings.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.1159","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T08:47:27Z","timestamp":1357807647000},"page":"63-68","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Tigecycline\u2010Related Pancreatitis: A Review of Spontaneous Adverse Event Reports"],"prefix":"10.1002","volume":"33","author":[{"given":"Emmanuel","family":"Okon","sequence":"first","affiliation":[{"name":"Beth Israel Medical Center Newark New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Engell","sequence":"additional","affiliation":[{"name":"Beth Israel Medical Center Newark New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert","family":"van Manen","sequence":"additional","affiliation":[{"name":"Oracle Health Sciences Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Brown","sequence":"additional","affiliation":[{"name":"Schools of Pharmacy and Pharmaceutical Science State University of New York at Buffalo Buffalo New York"},{"name":"School of Public Health and the Department of Pharmacy University of Rochester Medical Center Rochester New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,10]]},"reference":[{"issue":"4","key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/medicina46040033","article-title":"Tigecycline\u2014how powerful is it in the fight against antibiotic\u2010resistant bacteria?","volume":"46","author":"Seputiene V","year":"2010","journal-title":"Medicina (Kaunas)"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/431672"},{"key":"e_1_2_6_4_1","volume-title":"Tygacil (tigecycline) prescribing information","author":"Wyeth Pharmaceuticals, Inc","year":"2010"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.05.004"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181e83a85"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365540801938949"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318164939c"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4403-239"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr597"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.4.451"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225060-00001"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0016-5085(81)80024-8","article-title":"Tetracycline\u2010induced pancreatitis","volume":"81","author":"Elmore MF","year":"1981","journal-title":"Gastroneterology"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/21548331.1985.11703057"},{"key":"e_1_2_6_15_1","unstructured":"U.S. Food and Drug Administration.FDA drug safety communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections (Sept 2010). Available fromhttp:\/\/www.fda.gov\/DrugsSafety\/ucm224370.htm. Accessed November 14 2011."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.11.023"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1002"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1159","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:24:40Z","timestamp":1761060280000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1002\/phar.1159"],"URL":"https:\/\/doi.org\/10.1002\/phar.1159","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"2013-01-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}